Results 171 to 180 of about 2,725 (202)

Efficacy of Midodrine, Octreotide and Albumin (MOA) for Type I Hepatorenal Syndrome (HRS 1)

, 2011
Eashen Liu, Pooja Singhal, Yasmin Karim, Franca B. Barton, James H. Lewis   +4 more
openalex   +1 more source

Rationale for the prevention of syncope trial IV: assessment of midodrine

, 2012
Satish R. Raj, Peter Faris, Maureen McRae, Robert S. Sheldon   +3 more
openalex   +2 more sources

Midodrine efficacy.

Australian prescriber
openaire   +1 more source

Midodrine for orthostatic hypotension.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Letter to the Editor: Midodrine for Hepatic Hydrothorax

Hepatology, 2021
We read with interest the article by Banini et al.1 They have succinctly described the pathophysiology and management of hepatic hydrothorax. We would like to share a few thoughts on the management of hepatic hydrothorax.
Anand V. Kulkarni, Mithun Sharma, Pramod Kumar, Rajesh Gupta, Padaki Nagaraja Rao   +4 more
openaire   +2 more sources

Midodrine in end-stage heart failure [PDF]

BMJ Supportive & Palliative Care, 2020
It is estimated that 5% of patients with heart failure (HF) will progress to end-stage disease refractory to medical therapy and might require prolonged hospitalisation with inotropic support. We present the case of a patient with end-stage HF who was admitted with cardiogenic shock.
Ariel Gonzalez-Cordero, Stephanie Ortiz-Troche, Juan Nieves-Rivera, Marcel Mesa-Pabón, Hilton Franqui-Rivera   +4 more
openaire   +2 more sources

Midodrine for the Treatment of Intradialytic Hypotension

Nephron, 1997
Recurrent intradialytic hypotension is probably the most severely disabling feature in dialysis patients and the etiology is multifactorial. We assessed the efficacy and safety of midodrine, a selective alpha1-adrenergic pressor agent in 12 patients with recurrent intradialytic hypotension.
Chin-Chin Yang, Chi-Hsiang Yeh, Han-Ping Li, Paik-Seong Lim, Yok-Tuan Lim   +4 more
openaire   +3 more sources

Midodrine

Chest, 2013
Thoracic duct injury is a rare but serious complication following surgery of the neck or chest that leads to uncontrolled chyle leak. Conventional management includes drainage, nutritional modification, or aggressive surgical interventions such as thoracic duct ligation, flap coverage, fibrin glue, or talc pleurodesis; few successful medical ...
Heather Warren, Ali Salim, Douglas Z. Liou, Nicolas Melo, Eric J. Ley, Dermot P. Maher, Harmik J. Soukiasian   +6 more
openaire   +3 more sources

Pharmacodynamics of midodrine, an antihypotensive agent

Clinical Pharmacology and Therapeutics, 1986
Midodrine is an orally active adrenergic agonist useful in the treatment of hypotension. We have investigated the pharmacodynamics of its active metabolite after oral midodrine therapy in nine patients with severe orthostatic hypotension. Peak plasma levels of the metabolite were reached in 60 to 90 minutes and ranged from 25 to 56 ng/ml.
Prince K. Zachariah, Prince K. Zachariah, Duane C Bloedow, Duane C Bloedow, Thomas P. Moyer, Thomas P. Moyer, Robert D. Fealey, Robert D. Fealey, Alexander Schirger, Alexander Schirger, Sheldon G. Sheps, Sheldon G. Sheps   +11 more
openaire   +3 more sources

Midodrine for the weaning of vasopressor infusions

Journal of Clinical Pharmacy and Therapeutics, 2016
Midodrine, an orally available α1-agonist indicated for the treatment of orthostatic hypotension, has been used at our institution as an adjunctive treatment to provide haemodynamic support to facilitate intravenous (IV) vasopressor weaning. Limited published data exist for this off-label use; thus, the objective of this study was to evaluate outcomes ...
L. B. Poveromo, Elizabeth Landrum Michalets, S. E. Sutherland   +2 more
openaire   +3 more sources